Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hemophilia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    275 result(s) found for: Hemophilia. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-001623-38 Sponsor Protocol Number: 060103 Start Date*: 2004-11-05
    Sponsor Name:Baxter AG
    Full Title: Phase 3B Recombinant Antihemophilic Factor Manufactured and Formulated without added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060612 Hemophilia A LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005253-39 Sponsor Protocol Number: BAY14-2222/12684 Start Date*: 2015-01-21
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated He...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001362-10 Sponsor Protocol Number: BAY14-2222/16287 Start Date*: 2014-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Routine prophylaxis treatment versus On-demand treatment for Children with severe Hemophilia A: comparison of all bleeding events in Chinese Hemophilia patients
    Medical condition: Patients with Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004834-18 Sponsor Protocol Number: 060601 Start Date*: 2008-02-22
    Sponsor Name:Baxter Innovations GmbH
    Full Title: PHARMACOKINETIC COMPARISON OF ADVATE rAHF-PFM WITH RECOMBINATE rAHF IN PATIENTS WITH SEVERE HEMOPHILIA A: A PHASE IV, PROSPECTIVE, RANDOMIZED, CONTROLLED, CROSS-OVER, SINGLE CENTER STUDY
    Medical condition: The objective of this study is to further evaluate observations of decreased efficacy in subjects having been switched to Advate rAHF-PFM from Recombinate rAHF by comparing the pharmacokinetic para...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066439 Hemophilia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003685-88 Sponsor Protocol Number: B1831082 Start Date*: 2016-04-19
    Sponsor Name:Pfizer Inc.
    Full Title: An Open-label, Single Dose Pharmacokinetic Study Of Xyntha (moroctocog Alfa (af-cc), Recombinant Factor VIII) In Male Chinese Subjects With Hemophilia A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002396-99 Sponsor Protocol Number: NN7170-4213 Start Date*: 2016-10-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: AT (Completed) DE (Completed) BG (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000806-39 Sponsor Protocol Number: BAY2599023/19429 Start Date*: 2019-02-25
    Sponsor Name:Bayer AG
    Full Title: A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with sever...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002757-45 Sponsor Protocol Number: 11859 Start Date*: 2005-11-28
    Sponsor Name:Bayer HealthCare LLC/Biological Products
    Full Title: A prospective controlled study on the effect on bleeding events and joint function in young adults with severe hemophilia A after a 6 month prophylaxis treatment compared to on demand treatment
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    7.1 10018937 low
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005040-33 Sponsor Protocol Number: B1831083 Start Date*: 2016-12-14
    Sponsor Name:Pfizer, Inc.
    Full Title: An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (moroctocog-alfa (af-cc), Recombinant FVIII) In Subjects With Hemophilia A In Usual Care...
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10018937 Haemophilia A LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001464-11 Sponsor Protocol Number: ALN-AT3SC-004 Start Date*: Information not available in EudraCT
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ATLAS-A/B: A Phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX
    Medical condition: Hemophilia A or Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000011915 10060613 Hemophilia A (Factor VIII) LLT
    20.0 100000011913 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IE (Prematurely Ended) BG (Completed) HU (Completed) ES (Prematurely Ended) PT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) NL (Not Authorised) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001336-65 Sponsor Protocol Number: CSL627_3002 Start Date*: 2013-11-27
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population with Severe Hemophilia A
    Medical condition: Congenital hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: HU (Prematurely Ended) DE (Completed) ES (Completed) NL (Completed) IT (Completed) PT (Completed) PL (Completed) AT (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001463-36 Sponsor Protocol Number: EFC14768 Start Date*: 2018-07-25
    Sponsor Name:Genzyme Corporation
    Full Title: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX
    Medical condition: Hemophilia A or Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed) HU (Completed) ES (Prematurely Ended) PT (Completed) FR (Completed) DE (Completed) DK (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004570-21 Sponsor Protocol Number: B1831097 Start Date*: 2020-10-13
    Sponsor Name:Pfizer, Inc.
    Full Title: A SINGLE COUNTRY, MULTICENTER, OPEN-LABEL AND NON-RANDOMIZED CLINICAL TRIAL WITH MOROCTOCOG ALFA (AF-CC) PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATE ...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-007347-13 Sponsor Protocol Number: 060801 Start Date*: 2009-07-13
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Advate (rAHF-PFM): Pharmacokinetic comparison of 3000 IU Advate (rAHF-PFM) (using one 3000 IU potency vial) with 3000 IU Advate (rAHF-PFM) (using two 1500 IU potency vials) in previously treated pa...
    Medical condition: severe hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060612 Hemophilia A LLT
    Population Age: Adults Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004106-15 Sponsor Protocol Number: 3082B2-3316 Start Date*: 2015-04-03
    Sponsor Name:Wyeth Pharmaceutical Co., Ltd
    Full Title: An Evaluation of the Safety and Efficacy of On-Demand Treatment with Xyntha (B-Domain Deleted Recombinant Factor VIII, Albumin Free) in Chinese Subjects with Hemophilia A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10018937 Haemophilia A LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-001026-34 Sponsor Protocol Number: CSL627_3003 Start Date*: 2024-12-19
    Sponsor Name:CSL Behring
    Full Title: A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) with Hem...
    Medical condition: Congenital Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-023242-69 Sponsor Protocol Number: GENA-11 Start Date*: 2011-05-31
    Sponsor Name:Octapharma AG
    Full Title: Clinical Study to Investigate the Long-Term Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients with Severe Haemophilia A – Extension Study to GENA-01
    Medical condition: Severe haemophilia A (FVIII:C <1%)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-002456-24 Sponsor Protocol Number: 3082B2-4418 Start Date*: 2015-04-10
    Sponsor Name:Wyeth Research
    Full Title: A Post Authorization Safety Surveillance Study of Xyntha in Usual Care Settings
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003718-32 Sponsor Protocol Number: BAY79-4980/12781 Start Date*: 2008-06-27
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week proph...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060613 Hemophilia A (Factor VIII) LLT
    9.1 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) ES (Completed) BE (Completed) AT (Completed) GB (Completed) IT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-003072-37 Sponsor Protocol Number: 8HA01EXT Start Date*: 2012-01-18
    Sponsor Name:Biogen Idec Research Ltd
    Full Title: An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episode...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    19.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) BE (Completed) GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) IE (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:38:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA